Highland Peak Capital LLC Has $5.39 Million Position in Grifols, S.A. (NASDAQ:GRFS)

Highland Peak Capital LLC lowered its stake in Grifols, S.A. (NASDAQ:GRFS) by 36.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 607,096 shares of the biotechnology company’s stock after selling 343,115 shares during the period. Grifols makes up about 2.4% of Highland Peak Capital LLC’s investment portfolio, making the stock its 9th largest holding. Highland Peak Capital LLC’s holdings in Grifols were worth $5,391,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. GAMMA Investing LLC raised its position in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,135 shares during the period. NBC Securities Inc. lifted its position in Grifols by 2.8% in the 3rd quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock worth $463,000 after buying an additional 1,433 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares in the last quarter. US Bancorp DE boosted its position in Grifols by 12.3% during the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 2,256 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its position in Grifols by 5.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 58,677 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 2,790 shares in the last quarter.

Grifols Stock Up 1.7 %

GRFS stock opened at $8.60 on Thursday. The company has a 50-day moving average of $8.87 and a two-hundred day moving average of $8.04. Grifols, S.A. has a 52-week low of $5.30 and a 52-week high of $12.15. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.